Please assess the completion status of the following clinical trial:

Trial Title: TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer patients in curative setting, with port a cath Implantation for systemic chemotherapy, including neo-adjuvant and adjuvant chemo-immunotherapy and supportive therapy (e.g. parenteral Nutrition)~* Completion of curative Treatment with port a cath indication, operation included, regardless of a non-intravenous (subcutaneous or oral) given therapy (endocrine therapy, chemo-immunotherapy, radiotherapy)~* patients with pectoral port a cath systems~* No port a cath associated complications during curative therapy such as investigated events: persistent malfunction, thrombosis, infection of the port-a-cath (to puncture the port a cath under X-ray control is allowed except it results in diangosis of persistent malfunction)~* No therapeutic anticoagulant therapy (phenprocoumon/Marcoumar®, heparin)~* No evidence of metastatic disease~* ≥18 years~* Willing to participate~Exclusion Criteria:~* No signed informed consent~* Patients with port a cath systems other than pectoral port a cath systems (e.g. forearm port a cath System)~* Unable to attend control timepoints~* Use of the port-a-cath after the above defined curative treatment (within the investigational period)~* Willing to explant the port-a-cath~* Willing to become pregnant within one year after adjuvant treatment~* Patient with heparin-induced Thrombocytopenia (HIT)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 6 months (Type: EXPERIMENTAL): evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
- 12 months (Type: EXPERIMENTAL): evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase

Based on this trial design, predict the completion outcome and termination type (if applicable).